Sean Cooke
Thesis title: Inhibiting MDM2 Dimerisation as a Novel Therapeutic Approach for Acute Myeloid Leukaemia
Precision Medicine
Year of study: 1
- Paul O' Gorman Leukaemia Research Centre
- University of Glasgow
Contact details
- Email: s.cooke.1@research.ac.uk
PhD supervisors:
Background
First-year PhD student on the MRC funded Precision Medicine (iCASE) programme, based at the University of Glasgow. Graduated with an MSc (by research) in Molecular Pharmacology (2023) and BSc (Hons) in Biochemistry (2021), also from the University of Glasgow. Previous experience in developing novel therapeutic approaches for the treatment of pancreatic and prostate cancer.
Qualifications
MSc (by research) Molecular Pharmacology, University of Glasgow (2023)
BSc (Hons) Biochemistry, University of Glasgow (2021)
Research summary
Research interests include cancer, drug discovery & development, leukaemia, precision medicine, protein-protein interactions, peptides, MDM2, p53
Project activity
PhD project investigates a precision medicine approach to treat Acute Myeloid Leukaemia (AML), emphasising the importance of molecular and genetic profiling to tailor treatment strategies for patients. Specifically, exploring the inhibition of MDM2/MDMX dimerisation as a novel therapeutic strategy for AML, offering potential benefits beyond traditional p53-dependent approaches to target MDM2 in cancer.